MARKET

CELG

CELG

Celgene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

108.24
0.00
0.00%
Delisted 09:30 03/27 EDT
OPEN
--
PREV CLOSE
108.13
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
110.70
52 WEEK LOW
58.59
MARKET CAP
77.00B
P/E (TTM)
13.50
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CELG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CELG stock price target is 104.00 with a high estimate of 116.00 and a low estimate of 86.00.

EPS

CELG News

More
  • European advisory group backs Celgene's ozanimod for type of multiple sclerosis
  • seekingalpha · 2d ago
  • The No. 1 Pharma Company Nabbed A Key Approval But Is It A Buy?
  • Investor's Business Daily · 3d ago
  • Tracking David Rolfe's Wedgewood Partners Portfolio - Q4 2019 Update
  • Seeking Alpha - Article · 3d ago
  • Is The No. 1 Pharma Stock A Buy Following Its Massive Acquisition?
  • Investor's Business Daily · 4d ago

Industry

Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About CELG

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More

Webull offers kinds of Celgene Corporation stock information, including NASDAQ:CELG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG stock news, and many more online research tools to help you make informed decisions.